The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan-Reference-Cited by-同舟云学术

The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan

Published:2023-09-24 Issue:10 Volume:23 Page:1061-1069
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Schreiber Anna R.¹^ORCID,O’Bryant Cindy L.²,Kabos Peter¹,Diamond Jennifer R.¹

Affiliation:

1. Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

2. Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Funder

funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2257885

Reference54 articles.

1. National Cancer Institute: Surveillance E. and End Results Program. Cancer stat facts: female breast cancer subtypes . 2023 [cited 2023 Jun 1]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html

2. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

3. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

4. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary

5. HER2-Low Breast Cancer: Pathological and Clinical Landscape

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer;Breast Cancer Research and Treatment;2024-04-24

2. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01